Results for the substance sparsentan

Sparsentan is a medication under approval and use for the treatment of rare kidney diseases such as focal segmental glomerulosclerosis (FSGS). It works by simultaneously blocking endothelin and angiotensin II receptors, reducing pressure on kidney glomeruli and slowing disease progression.

The drug is taken orally as tablets and is typically used long-term as part of a complex treatment regimen. The dosage is personalized based on the severity of the disease and the patient’s profile.

Side effects may include low blood pressure, swelling (edema), liver function changes, or increased blood potassium levels. Therefore, careful monitoring of biological parameters is necessary during treatment.

Sparsentan provides a promising approach for kidney diseases with limited treatment options, but its use must be strictly managed under specialist supervision.